TY - JOUR
T1 - Do airway metallic stents for benign lesions confer too costly a benefit?
AU - Chan, Andrew
AU - Juarez, Maya M.
AU - Allen, Roblee P
AU - Albertson, Timothy E
PY - 2008/4/18
Y1 - 2008/4/18
N2 - Background: The use of self-expanding metallic stents (SEMAS) in the treatment benign airway obstruction is controversial. Methods: To evaluate the safety and efficacy of SEMAS for this indication, we conducted a 10-year retrospective review at our tertiary medical centre. Results: Using flexible bronchoscopy, 82 SEMAS (67% Ultraflex, 33% Wallstent) were placed in 35 patients with inoperable lesions, many with significant medical comorbidities (88%). 68% of stents were tracheal, and 83% of patients showed immediate symptomatic improvement. Reversible complications developed in 9% of patients within 24 hrs of stent placement. Late complications (>24 hrs) occurred in 77% of patients, of which 37% were clinically significant or required an interventional procedure. These were mainly due to stent migration (12.2%), fracture (19.5%), or obstructive granulomas (24.4%). The overall granuloma rate of 57% was higher at tracheal sites (59%) than bronchial ones (34%), but not significantly different between Ultraflex and Wallstents. Nevertheless, Wallstents were associated with higher rates of bleeding (5% vs. 30%, p = 0.005) and migration (7% vs. 26%, p = 0.026). Of 10 SEMAS removed using flexible bronchoscopy, only one was associated with incomplete removal of fractured stent wire. Median survival was 3.6 ± 2.7 years. Conclusion: Ill patients with inoperable lesions may be considered for treatment with SEMAS.
AB - Background: The use of self-expanding metallic stents (SEMAS) in the treatment benign airway obstruction is controversial. Methods: To evaluate the safety and efficacy of SEMAS for this indication, we conducted a 10-year retrospective review at our tertiary medical centre. Results: Using flexible bronchoscopy, 82 SEMAS (67% Ultraflex, 33% Wallstent) were placed in 35 patients with inoperable lesions, many with significant medical comorbidities (88%). 68% of stents were tracheal, and 83% of patients showed immediate symptomatic improvement. Reversible complications developed in 9% of patients within 24 hrs of stent placement. Late complications (>24 hrs) occurred in 77% of patients, of which 37% were clinically significant or required an interventional procedure. These were mainly due to stent migration (12.2%), fracture (19.5%), or obstructive granulomas (24.4%). The overall granuloma rate of 57% was higher at tracheal sites (59%) than bronchial ones (34%), but not significantly different between Ultraflex and Wallstents. Nevertheless, Wallstents were associated with higher rates of bleeding (5% vs. 30%, p = 0.005) and migration (7% vs. 26%, p = 0.026). Of 10 SEMAS removed using flexible bronchoscopy, only one was associated with incomplete removal of fractured stent wire. Median survival was 3.6 ± 2.7 years. Conclusion: Ill patients with inoperable lesions may be considered for treatment with SEMAS.
UR - http://www.scopus.com/inward/record.url?scp=44149099551&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44149099551&partnerID=8YFLogxK
U2 - 10.1186/1471-2466-8-7
DO - 10.1186/1471-2466-8-7
M3 - Article
C2 - 18423035
AN - SCOPUS:44149099551
VL - 8
JO - BMC Pulmonary Medicine
JF - BMC Pulmonary Medicine
SN - 1471-2466
M1 - 7
ER -